Cargando…
Profile of ustekinumab and its potential in patients with moderate-to-severe Crohn’s disease
The advent of anti-tumor necrosis factor (TNF)-α therapy has been a major advance in the medical management of Crohn’s disease (CD). However, a significant proportion of patients with CD do not respond adequately to treatment with these agents. Primary and secondary nonresponse to anti-TNFα therapy...
Autores principales: | Tuskey, Anne, Behm, Brian W |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4041179/ https://www.ncbi.nlm.nih.gov/pubmed/24904220 http://dx.doi.org/10.2147/CEG.S39518 |
Ejemplares similares
-
Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
por: Hansson-Hedblom, Amanda, et al.
Publicado: (2018) -
Clinical utility of ustekinumab in Crohn’s disease
por: Kotze, Paulo Gustavo, et al.
Publicado: (2018) -
Ustekinumab in treatment of Crohn’s disease: design, development, and potential place in therapy
por: Deepak, Parakkal, et al.
Publicado: (2016) -
Hypersensitivity to IV Ustekinumab but Tolerance to Subcutaneous Ustekinumab in a Patient With Crohn's Disease
por: Krugliak Cleveland, Noa, et al.
Publicado: (2020) -
Case Series: Re-induction of Intravenous, Weight-Based Ustekinumab Is Well Tolerated in Patients With Moderate–Severe Crohn’s Disease
por: Lee, Scott David, et al.
Publicado: (2022)